Neurodevelopment After Prenatal Exposure to Newer Epilepsy Drugs Tracked for 3 Years
Children with fetal exposure to newer antiseizure medications showed no difference in neurodevelopmental outcomes at age 3 compared with unexposed children, data from the ongoing MONEAD study showed. In the prospective observational study, mean verbal index scores at age 3 did not differ for children of women with epilepsy (102.7) versus those born to mothers […]
Real-World Data Affirms Next-Gen TAVR Device Advantage
PHOENIX — The newer generation Evolut transcatheter aortic valve replacement (TAVR) device improved on procedural and possibly safety characteristics, the TVT registry showed. The Evolut FX device reduced need for device repositioning and cut procedure time, without a change in valve hemodynamics, at 30 days compared with the Evolut Pro+ device, reported Wah Wah Htun, […]
Novel Anti-HER2 Drugs ‘Impressive’ in Advanced Biliary Cancer
CHICAGO — In a pair of mid-stage trials, newer targeted therapies demonstrated meaningful levels of activity against HER2-positive biliary tract cancers in pretreated patients with advanced disease. Cohort 1 of the global HERIZON-BTC-01 study, which included 80 treatment-refractory patients, showed that 41.3% (95% CI 30.4-52.8) responded to zanidatamab, an investigational bispecific monoclonal antibody that targets […]
Trial: Functional Scoring a Better Guide to Neonatal Opioid Withdrawal Tx
A newer function-based approach to treating neonatal opioid withdrawal syndrome safely readied babies to go home sooner, the ACT NOW randomized trial showed. With the Eat, Sleep, Console care approach, time from birth to medical readiness for hospital discharge by American Academy of Pediatrics-endorsed standards was nearly a week sooner than when treating guided by […]
SGLT2 Inhibitors, GLP-1 RAs Not Cost-Effective as First-Line T2D Agents
Although using newer classes of diabetes drugs as first-line therapy can boost life expectancy, this strategy can be quite pricey, according to a cost-effectiveness study. Compared with traditional first-line metformin, first-line SGLT2 inhibitors cost $43,000 more over a lifetime, and first-line GLP-1 receptor agonists cost $49,000 more, reported Neda Laiteerapong, MD, MS, of the University […]